Donald McDonnell, Professor in the Department of Pharmacology and Cancer Biology at Duke University School of Medicine, shared a post on LinkedIn:
“More good news for patients with ER-positive breast cancer. Lasofoxifene was originally developed in the early 1990s at Ligand Pharmaceuticals as a treatment for osteoporosis.
However, a remarkable graduate student in my laboratory, Kaitlyn Andreano, discovered that this ‘old drug’ was an extremely effective inhibitor of the estrogen receptor mutations that drove resistance to first-line endocrine therapies in patients with metastatic breast cancer.
The enabling intellectual property that emerged from this work was licensed by Duke to Sermonix… and as they say, the rest was history! I have a very high level of confidence that this drug will become a part of the oncologist’s armamentarium!”
More posts featuring Donald McDonnell.